Skip to main content
AAN.com
Research Articles
May 26, 2022
Open Accesspodcast

Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease
Evidence From the COURAGE-PD Consortium

Sandeep Grover, PhD https://orcid.org/0000-0003-2615-4916, Ashwin Ashok Kumar Sreelatha, MTech, Lasse Pihlstrom, MD https://orcid.org/0000-0002-7635-8645, Cloé Domenighetti, PhD https://orcid.org/0000-0001-6408-0351, Claudia Schulte, MSC, Pierre-Emmanuel Sugier, PhD, Milena Radivojkov-Blagojevic, MSc, Peter Lichtner, PhD, Océane Mohamed, MSc, Berta Portugal, PhD, Zied Landoulsi, PhD, Patrick May, PhD https://orcid.org/0000-0001-8698-3770, Dheeraj Bobbili, PhD, Connor Edsall, PhD https://orcid.org/0000-0001-6876-1496, Felix Bartusch, MSc https://orcid.org/0000-0003-0711-5196, Maximilian Hanussek, MSc https://orcid.org/0000-0002-2598-4398, Jens Krüger, PhD https://orcid.org/0000-0002-2636-3163, Dena G. Hernandez, PhD, Cornelis Blauwendraat, PhD, George D. Mellick, PhD, Alexander Zimprich, MD, Walter Pirker, MD, Manuela Tan, MSC, Ekaterina Rogaeva, PhD, Anthony Lang, MD, Sulev Koks, MD, PhD https://orcid.org/0000-0001-6087-6643, Pille Taba, MD, PhD, Suzanne Lesage, PhD, Alexis Brice, Jean-Christophe Corvol, MD, PhD, Marie-Christine Chartier-Harlin, PhD, Eugenie Mutez, MD, PhD, Kathrin Brockmann, MD, Angela B. Deutschländer, MD, Georges M. Hadjigeorgiou, MD, Efthimos Dardiotis, MD, Leonidas Stefanis, MD, PhD, Athina Maria Simitsi, MD, PhD, Enza Maria Valente, MD, PhD https://orcid.org/0000-0002-0600-6820, Simona Petrucci, MD, PhD, Letizia Straniero, PhD https://orcid.org/0000-0002-1733-7561, Anna Zecchinelli, MD, Gianni Pezzoli, MD https://orcid.org/0000-0003-4665-6710, Laura Brighina, MD, PhD, Carlo Ferrarese, MD, PhD, Grazia Annesi, PhD, Andrea Quattrone, MD, Monica Gagliardi, PhD, Lena F. Burbulla, PhD, Hirotaka Matsuo, MD, PhD, Yusuke Kawamura, MD, Nobutaka Hattori, MD, PhD, Kenya Nishioka, MD, PhD, Sun Ju Chung, MD, PhD, Yun Joong Kim, MD, PhD https://orcid.org/0000-0002-2956-1552, Lukas Pavelka, MD, Bart P.C. van de Warrenburg, MD, PhD, Bastiaan R. Bloem, MD, PhD, Andrew B. Singleton, PhD, Jan Aasly, MD, Mathias Toft, MD, PhD https://orcid.org/0000-0002-6723-6865, Leonor Correia Guedes, MD, PhD, Joaquim J. Ferreira, MD, PhD, Soraya Bardien, PhD https://orcid.org/0000-0002-3508-3438, Jonathan Carr, PhD, Eduardo Tolosa, MD, PhD, Mario Ezquerra, PhD, Pau Pastor, MD, PhD https://orcid.org/0000-0002-7493-8777, Monica Diez-Fairen, MSc, Karin Wirdefeldt, MD, PhD, Nancy L. Pedersen, PhD, Caroline Ran, PhD, Andrea C. Belin, PhD, Andreas Puschmann, MD, PhD, Clara Hellberg, MD, Carl E. Clarke, MD, Karen E. Morrison, MD, Dimitri Krainc, MD, PhD https://orcid.org/0000-0002-4716-1886, Matt J. Farrer, PhD https://orcid.org/0000-0003-1159-5321, Rejko Kruger, MD https://orcid.org/0000-0003-4258-6241, Alexis Elbaz, PhD https://orcid.org/0000-0001-9724-5490, Thomas Gasser, MD, and Manu Sharma, PhD and the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) ConsortiumAuthors Info & Affiliations
August 16, 2022 issue
99 (7) e698-e710

Abstract

Background and Objectives

Considerable heterogeneity exists in the literature concerning genetic determinants of the age at onset (AAO) of Parkinson disease (PD), which could be attributed to a lack of well-powered replication cohorts. The previous largest genome-wide association studies (GWAS) identified SNCA and TMEM175 loci on chromosome (Chr) 4 with a significant influence on the AAO of PD; these have not been independently replicated. This study aims to conduct a meta-analysis of GWAS of PD AAO and validate previously observed findings in worldwide populations.

Methods

A meta-analysis was performed on PD AAO GWAS of 30 populations of predominantly European ancestry from the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) Consortium. This was followed by combining our study with the largest publicly available European ancestry dataset compiled by the International Parkinson Disease Genomics Consortium (IPDGC).

Results

The COURAGE-PD Consortium included a cohort of 8,535 patients with PD (91.9%: Europeans and 9.1%: East Asians). The average AAO in the COURAGE-PD dataset was 58.9 years (SD = 11.6), with an underrepresentation of females (40.2%). The heritability estimate for AAO in COURAGE-PD was 0.083 (SE = 0.057). None of the loci reached genome-wide significance (p < 5 × 10−8). Nevertheless, the COURAGE-PD dataset confirmed the role of the previously published TMEM175 variant as a genetic determinant of the AAO of PD with Bonferroni-corrected nominal levels of significance (p < 0.025): (rs34311866: β(SE)COURAGE = 0.477(0.203), pCOURAGE = 0.0185). The subsequent meta-analysis of COURAGE-PD and IPDGC datasets (Ntotal = 25,950) led to the identification of 2 genome-wide significant association signals on Chr 4, including the previously reported SNCA locus (rs983361: β(SE)COURAGE+IPDGC = 0.720(0.122), pCOURAGE+IPDGC = 3.13 × 10−9) and a novel BST1 locus (rs4698412: β(SE)COURAGE+IPDGC = −0.526(0.096), pCOURAGE+IPDGC = 4.41 × 10−8).

Discussion

Our study further refines the genetic architecture of Chr 4 underlying the AAO of the PD phenotype through the identification of BST1 as a novel AAO PD locus. These findings open a new direction for the development of treatments to delay the onset of PD.
In 2019, over 8.51 million individuals (95% uncertainty interval 7.3–9.8) had Parkinson disease (PD) globally.1This disease is one of the fastest-growing neurodegenerative diseases with an estimated 30.9% increase in the number of patients with PD in 2019 compared with 2010. However, the prevalence of a disease depends on both the incidence and duration of disease, making an earlier age at onset (AAO) of PD an essential contributor to the overall burden of the disease. Although less than 5% of patients with PD harbor pathogenic variants in known monogenic PD genes, the majority are sporadic with predominantly late AAO.2,3 A better understanding of genetic factors influencing variability in AAO in sporadic patients could improve our understanding of PD pathophysiology.
The emergence of genome-wide association studies (GWAS) has resulted in a rapidly expanding list of loci harboring disease-susceptibility variants for the sporadic form of the disorder.4-6 To date, genetic variants at 78 loci have been identified for sporadic PD.6 Despite advances in understanding the genetic basis of PD, the heritability underlying PD AAO remains largely unexplained. A recent global effort involving 28,568 patients with sporadic PD of European ancestry led to the identification of 2 loci, SNCA and TMEM175, as risk factors for an earlier AAO, both of which are also known to play a role in α-synuclein–linked mechanisms underlying PD pathology.1,7,8 More recently, a meta-analysis including 5,166 Chinese patients with PD lead to the identification of another locus NDN/PWRN4.9 Despite the large disparity in sample size and the genetic loci identified by the 2 studies, both works estimated a similar total heritability of the AAO of 10%–14%.7,9 They also showed an indirect correlation between a polygenic risk score (PRS) and AAO based on risk loci for PD on individuals of similar ancestry, suggesting an overlap between the pathways underlying disease susceptibility and AAO in PD.
Recent studies have underscored the relevance of inclusion of ethnic diversity in genomic research.9,10 The COmprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) is a worldwide collaboration consortium comprising 35 PD study cohorts, which aims to address this disparity to some extent in PD research.11 This study aims to perform an AAO GWAS in COURAGE-PD and to investigate the validity of previously observed loci by conducting one of the largest meta-analysis of PD AAO GWAS to date by combining previous International Parkinson Disease Genomics Consortium (IPDGC) AAO GWAS (n = 17, 415) with newly generated COURAGE-PD AAO GWAS (n = 8,535), resulting in a combined dataset of 25,950 patients with PD. Finally, we investigate the influence of a PD PRS on PD AAO to dissect the potential overlapping etiology.

Methods

Study Cohorts and Participants

The COURAGE-PD Consortium comprises data from 15,849 patients with PD and 11,444 controls of predominantly European ancestry from 35 cohorts with a major contribution from the Genetic Epidemiology of Parkinson's Disease Consortium (geopd.net). Quality control (QC) of genome-wide data was performed in each COURAGE-PD study cohort. See eMethods, links.lww.com/WNL/C87, for more details, including collected phenotypic data. AAO was defined based on the initial manifestation of motor symptoms associated with PD, as described elsewhere.6 After imputation, only patients with potential sporadic PD with data available on AAO and not overlapping with previous IPDGC AAO GWAS were included in this study, leaving 8,535 samples from 30 cohorts. These comprised 26 European and 4 East Asian ancestry cohorts.

Genotype–Phenotype Analysis

Regression Analysis and Meta-analysis of Study-specific Estimates

Linear regression analysis of imputed dosages with AAO was performed in each study cohort using an additive model, implemented in rvtests, correcting for gender and the first 5 principal components.12 The selection of 5 principal components was based on study cohort–specific scree plots. The scree plot flattened out after the third factor for most study cohorts, with few exceptions, where 5 factors explained the highest proportion of the total variance. This was followed by combining study-specific results through inverse variance–weighted fixed-effect meta-analyses conducted using METAL.13,14 In addition, only those variants that were successfully genotyped in at least 2/3rd of study cohorts were included for further interpretation. Similarly, the variants with I2 statistic ≥ 50% were considered to have substantial heterogeneity and were excluded from further interpretation. We also used additive random-effect meta-analyses using the DerSimonian-Laird estimator to check the influence of heterogeneity on our findings.15 The quantile-quantile (QQ) plot was generated using R to judge the potential influence of population stratification on the overall significance of the effect estimates. We considered p < 5 × 10−8 as genome-wide significant and p < 1 × 10−6 as suggestive evidence for a potential association.9 We also considered Bonferroni-corrected p < 0.025 for reporting replication signals originating from 2 single-nucleotide variations (SNVs [formerly SNPs]; rs356203 [SNCA] and rs34311866 [TMEM175]) that reached a genome-wide significance in the previous largest meta-analysis of the AAO of PD.7 The results were visualized using R generated Manhattan and LocusZoom generated regional association plots.16 We conducted linkage disequilibrium (LD) score regression with LDSC (using summary-level data) to estimate heritability explained by the PD AAO GWAS.17 We also performed a meta-analysis of COURAGE-PD AAO (n = 8,535) with the previous largest AAO meta-analysis comprising IPDGC dataset (n = 17,415) to discover potentially new loci and improve heritability estimates.7

Correlation Between Case-Control GWAS and AAO GWAS

We used 2 approaches to assess the correlation between PD case-control GWAS meta-analysis and COURAGE-PD AAO GWAS meta-analysis. First, we computed the genome-wide genetic correlation between PD status and PD AAO in COURAGE-PD dataset using the cross-trait LD score regression method.17 Second, we used effect estimates of significant genetic variants (p < 5 × 10−8) identified by combining the COURAGE-PD case-control GWAS meta-analysis dataset with the IPDGC-PD case-control GWAS meta-analysis dataset to generate individual-specific PRSs in the COURAGE-PD AAO population, using PRSice2.18 Linear regression analysis of the PRS with AAO was performed, correcting for gender and the first 5 principal components.

Subgroup Analysis and Power Computation

A subgroup analysis was performed to explore the influence of ethnicity and gender on the AAO GWAS and the correlation between case-control and AAO GWAS meta-analyses. The power was estimated using QUANTO 1.2.4.19

Expression Quantitative Trait Loci Analysis

We further explored the potential influence of novel variants identified in this study on the expression traits using the gene expression data from the Genotype-Tissue Expression Project using the Genotype-Tissue Expression (GTEx) portal (gtexportal.org, Data Source: GTEx Analysis Release V8 (dbGaP Accession phs000424.v8.p2)) and the UK Brain Expression Consortium (UKBEC) using the Braineac portal (braineac.org).20,21

Standard Protocol Approvals, Registrations, and Patient Consents

This study was conducted at the University of Tübingen, and the ethical approval was obtained by the local institutional review board of the respective study sites. All the study participants provided signed informed consent.

Data Availability

Summary statistics of COURAGE-PD AAO GWAS used in the meta-analysis are available from the corresponding author on reasonable request. In addition, IPDGC summary statistics for AAO GWAS were downloaded from the IPDGC website (pdgenetics.org/resources). Significant SNVs of the risk of PD based on the meta-analysis of COURAGE-PD and IPDGC datasets used in the PRS calculation can be found in the original publication (Grover et al. in preparation). Relevant programming scripts used for the present work are available at the GitHub website of the Center for Genetic Epidemiology at Tübingen (github.com/CGEatTuebingen/Ageatonset_GWAS_Courage-PD).

Results

Main Study Outcome Variable

The final cohort after QC included a total of 8,535 patients with PD, 7,847 of European ancestry (91.9%) and 688 of East Asian ancestry (9.1%). The average AAO in the COURAGE-PD dataset was 58.9 years (SD = 11.6), with an underrepresentation of females (40.2%) (eTable 1, links.lww.com/WNL/C88). We did not observe any major influence of gender or ethnicity on AAO. Furthermore, the average AAO was slightly lower than that reported in the IPDGC dataset (62.1 years; SD = 12.1), a difference that was statistically significant (p < 0.05).

Genetic Heritability of the Study Outcome

Using summary-level data, the total estimated heritability (h2) in the COURAGE-PD dataset was 0.083 (SE = 0.057). Similar heritability estimates were observed in the European subcohort (h2 = 0.079, SE = 0.061). However, the heritability estimates in the Asian subcohort could not be reliably computed because of an insufficient number of patients. In addition, we failed to achieve any improvement in heritability estimates, although with improved accuracy by combining COURAGE-PD with the IPDGC dataset (h2 = 0.078, SE = 0.018).

Genome-wide Meta-analysis

COURAGE-PD

GWAS meta-analysis
The genomic inflation factor λ was 1.016 (see eFigure 1, links.lww.com/WNL/C86, for the QQ plot). None of the loci reached genome-wide significance (Figure 1). We observed 1 locus reaching the suggestive genome-wide significance level, PDZPH1P (Chr 5) (β(SE)COURAGE = −1.456(0.293), pCOURAGE = 6.91 × 10−7). However, stratifying the analyses by ethnicities, we did not observe any suggestive involvement of PDZPH1P locus in the European subcohort (eTable 2, links.lww.com/WNL/C88). Of interest, despite being a smaller subcohort, SUGCT locus on chromosome (Chr) 7 was detected as a suggestive locus in the East Asian subcohort (β(SE)COURAGE-EASIAN = 13.681(2.769), pCOURAGE-EASIAN = 7.80 × 10−7). Furthermore, the stratified analysis provided suggestive evidence of 3 loci, RHEB (Chr 8) in males (β(SE)COURAGE-M = −1.112(0.222), pCOURAGE-M = 5.15 × 10−7), MTHFD1L (Chr 6) in females (β(SE)COURAGE-F = −1.995(0.402), pCOURAGE-F = 6.78 × 10−7), and KNH3 (Chr 12) in females (β(SE)COURAGE-F = 2.176(0.432), pCOURAGE-F = 4.59 × 10−7) (eTable 2, links.lww.com/WNL/C88).
Figure 1 Manhattan Plot of COURAGE-PD Age-at-Onset GWAS
COURAGE-PD = Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease; GWAS = genome-wide association studies.
In the replication of previously reported variants, only the TMEM175 variant (rs34311866: β(SE)COURAGE = 0.477(0.203), pCOURAGE = 0.018) reached Bonferroni-corrected nominal levels of significance in the COURAGE-PD dataset. Nevertheless, the SNCA variant also showed a trend toward association (rs356203: β(SE)COURAGE = 0.362(0.172), pCOURAGE = 0.035).
Meta-analysis of COURAGE-PD and IPDGC Datasets
The meta-analysis of COURAGE-PD and IPDGC datasets led to the identification of 2 loci that reached genome-wide significance (eTable 2, links.lww.com/WNL/C88; Figure 2). The SNCA variant, rs983361, was the most strongly associated SNV, with the presence of allele T (frequency = 0.204) leading to an average delay in AAO by 0.72 years (β(SE)COURAGE+IPDGC = 0.720(0.122), pCOURAGE+IPDGC = 3.13 × 10−9). This association, however, appeared to be driven by the strong association reported by the IPDGC dataset, with negligible effect detected in the COURAGE-PD dataset (pCOURAGE/COURAGE-EUR (rs983361) = 0.022; not detected in the East Asian subpopulation) (eFigure 2A, links.lww.com/WNL/C86), which was also reflected in the loss of genome-wide significance, when using an additive random effect model (p = 2.98 × 10−6). On the other hand, another independent locus on the same chromosome, BST1 (rs4698412), showed similar effects in COURAGE-PD and IPDGC datasets (β(SE)COURAGE = −0.633(0.175), pCOURAGE = 2.95 × 10−4; β(SE)IPDGC = −0.480(0.115), pIPDGC = 3.04 × 10−5), and the combination of both estimates resulted in the identification of a novel genome-wide significant BST1 locus for AAO (β(SE)COURAGE+IPDGC = −0.526(0.096), pCOURAGE+IPDGC = 4.41 × 10−8) (eFigure 2B, links.lww.com/WNL/C86). The rs4698412 allele A (frequency = 0.562) at the locus led to an average earlier AAO of 0.526 years in patients with PD. No genetic heterogeneity was detected in the observed association (I2 = 0; heterogeneity p = 0.465). Furthermore, we did not observe any change in the effect estimates, when using the additive random effect model (p = 4.41 × 10−8).
Figure 2 Manhattan Plot of the Meta-analysis of COURAGE-PD and IPDGC Age-at-Onset GWAS
COURAGE-PD = Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease; GWAS = genome-wide association studies; IPDGC = International Parkinson Disease Genomics Consortium.
The previously reported TMEM175 (rs34311866) showed a suggestive association in the combined analysis (β(SE)COURAGE+IPDGC = 0.589(0.114), pCOURAGE+IPDGC = 2.64 × 10−7) that appeared to be driven by previously reported findings in the IPDGC dataset (β(SE)IPDGC = 0.642(0.139), pIPDGC = 3.72 × 10−6) (eFigure 2C, links.lww.com/WNL/C86). Another locus AL391867.1/RP11-342F21.1 (rs62582905), a locus of unknown biological significance, also crossed the threshold of a suggestive association in the same analysis (β(SE)COURAGE+IPDGC = −1.456(0.293), pCOURAGE = 6.62 × 10−7) (eTable 2, links.lww.com/WNL/C88). However, unlike the TMEM175 association, the association with AL391867.1/RP11-342F21.1 was observed to be stronger in the COURAGE-PD dataset (β(SE)COURAGE = −1.925(0.447), pCOURAGE = 1.64 × 10−5).
We performed a sensitivity analysis by excluding the Asian subcohort from the COURAGE dataset, followed by combining with the IPDGC dataset. Similar findings were observed for the 2 genome-wide significant loci (SNCA rs983361: pCOURAGE-EUR+IPDGC = 3.13 × 10−9, BST1 rs4698412: pCOURAGE-EUR+IPDGC = 6.27 × 10−8) (eTable 2, links.lww.com/WNL/C88). A similar sensitivity analysis for the previously reported APOE ε4 locus also showed a suggestive association with PD AAO (APOE rs429358: β(SE)COURAGE‐EUR+IPDGC = 0.711(0.145), pCOURAGE‐EUR +IPDGC = 9.33 × 10−7). However, the association was primarily driven by highly significant findings in the IPDGC dataset (β(SE)IPDGC = 0.754(0.171), pIPDGC = 9.86 × 10−6; β(SE)COURAGE‐EUR = 0.599(0.275), pCOURAGE‐EUR = 0.029).

Correlation Between Genetic Risk for PD and PD AAO

Using complete GWAS summary datasets for COURAGE-PD case-control and COURAGE-PD AAO, we observed a nonsignificant negative genetic correlation between PD and PD AAO (rg = −0.291, SE = 0.224; p = 0.186). Furthermore, a slightly stronger genetic correlation was observed when restricting our correlation analysis to European subcohorts alone (rg = −0.315; SE = 0.252; p = 0.211).
When using the PRS based on the significant loci detected in the meta-analysis of COURAGE-PD and IPDGC European datasets, as reported elsewhere, we observed that each unit increase in SD in the PRS leads to a significant decrease in AAO in COURAGE-PD by 0.58 years (β(SE)COURAGE = −0.581(0.149), pCOURAGE = 9.35 × 10−5). Despite the significant findings, the PRS explained only 0.59% of the genetic proportion of PD heritability.

Expression Quantitative Trait Analysis of Novel BST1 Locus

The mining of the GTEx portal showed that rs4698412 representing the BST1 locus is a highly significant expression quantitative trait locus (eQTL) for CD38 in the basal ganglia (caudate, nucleus accumbens, and putamen) and cortex (NES = −0.32–0.44; p < 1 × 10−10) (Table 1). The expression analysis also showed a strong dosage effect with a consistent lower expression in the presence of AA genotype compared with GG genotype with a higher expression, irrespective of the brain tissue type. In addition, we also found that SNV modulates the expression of BST1 in whole blood. However, the effect was considerably lower in comparison with that observed on CD38 expression levels in brain tissues (NES = −0.071; p = 1.7 × 10−6). The follow-up of the association of rs4698412 with expression in brain tissues in the UKBEC database further confirmed the role of basal ganglia, with CD38 as the most significantly associated expressed gene in the putamen (p = 7.1 × 10−6) (Table 1).
Table 1 eQTL Lookup of BST1 SNV rs4698412 From GTEx and UKBEC in Brain Tissue

Discussion

The identification of genetic determinants that modify the disease progression will not only help to increase our understanding of PD etiopathogenesis but also enable the development of strategies that could be used for therapeutic intervention for at-risk carriers. Our study not only validates previously reported AAO PD loci in the COURAGE-PD dataset, but our meta-analysis with IPDGC data also provides the first genome-wide significant evidence that the known BST1 PD risk locus affects AAO. Of interest, the variant, rs4698412, representing the BST1 locus, showed a similar large effect in COURAGE-PD and IPDGC, providing strong evidence that this is a bona fide genetic locus for PD AAO. Finally, using significant SNVs from the meta-analysis of COURAGE-PD and IPDGC case-control datasets, we demonstrate an inverse association between a PD PRS and AAO of PD.
Numerous genetic loci for familial and sporadic PD have been well characterized. The existence of overlapping loci between familial and sporadic PD suggests a complex but interconnected relationship between PD and age. Several meta-analyses of candidate genes and GWAS have previously recognized the BST1 locus as a locus that could influence the development of sporadic late-onset PD.6,22-24 Notably, the BST1 locus has been demonstrated to play a role in both Asian and European PD populations.6,22-24 The genome-wide significant BST1 variant, rs4698412 observed in our AAO meta-analysis, is also identical to the top BST1 variant reported in the latest PD GWAS meta-analysis.6 Of interest, regional plots showed that the genome-wide significant variant, rs4694812, was neither the top genetic variant in the BST1 locus in IPDGC nor COURAGE AAO PD datasets. Although rs4694819 (r2 with rs4694812 < 0.6) was the most significant variant in the COURAGE AAO dataset, rs11724635 (r2 with rs4698412 = 1.0) was the most significant variant in the IPDGC AAO dataset (eFigure 2B, links.lww.com/WNL/C86).
BST1 was first identified as a gene encoding a cell surface receptor on bone marrow stromal cells (bone marrow stromal cell antigen 1) with a role in promoting the growth of hematopoietic stromal cells.25 In addition to its role as a receptor, it also exhibits ADP-ribosyl cyclase activity, leading to the generation of cyclic ADP-ribose, with a role in intrinsic Ca2+ regulation.26 The dual functional protein, a highly conserved glycosylphosphatidylinositol-anchored glycoprotein (also known as CD157), is now known to be expressed in a wide variety of tissues, including the vascular endothelium and follicular dendritic cells, with an ability to perform a wide variety of immune system– and inflammation-related cellular functions.27 The initial identification of BST1/CD157 as a potential risk locus for sporadic late-onset PD in a GWAS in the Japanese population led to several functional studies aimed at deciphering its potential neuronal role in influencing the PD phenotype.22 Several knockout mouse model studies have shown that BST1 can influence social behavior. However, the studies failed to demonstrate any influence on motor functioning, the cardinal feature that is impaired in patients with PD.28,29 The eQTL analysis demonstrated a highly significant effect of the BST1 locus, rs4694812, on gene expression, with the A allele resulting in a decreased expression of CD38, a paralog of CD157, in a dose-dependent manner. CD38 and CD157 are contiguous gene duplicates, which belong to the same gene family with a similar role of dual functional protein and an ability to modulate social behavior.30,31 Of interest, unlike CD157, CD38 knockout mice have been shown to have higher locomotor activity.32 Furthermore, the highly significant increased expression of CD38 was mainly observed in the striatum, a region directly implicated in motor dysfunction in PD. Of interest, a statistically underpowered brain imaging study in humans suggested that allele A of BST1 SNV rs4698412 leads to deficits in the right lingual gyrus region in the brain during the progression of PD.33 This brain region is known to play a role in spatial orientation and visuospatial information processing. However, specific molecular and neuronal pathways influenced by altered CD38 expression in basal ganglia, with a potential role in triggering earlier AAO in sporadic PD, remain unclear.
SNCA is one of the most consistently observed significant loci in both early- and late-onset PD and has been suggested to play a critical role in the age-related hierarchy of disease onset. Although monogenic PD, often with relatively early onset, is attributed to rare point mutations and multiple copies of the SNCA gene, susceptibility to late-onset PD is attributed to common variants.6,10,34-36 In addition to being a leading locus in the largest GWAS of sporadic PD to date, the locus was also recently reported to be a top locus in influencing AAO in Europeans in meta-analyses comprising IPDGC and 23andMe datasets (n = 28,568).7 An SNV present toward the 3′ end (rs356203) of the SNCA gene was observed as the strongest genome-wide significant variant originating from the region (p = 1.9 × 10−12). Based on the conditional analysis, the study also identified an independent signal at the 5′ end of the gene, rs983361 (p = 6.8 × 10−6). A recent GWAS of AAO in 5,166 East Asian (Chinese) patients with PD further reported a slightly weaker signal originating from another independent SNCA variant, rs3775458 (p = 9.92 × 10−7).9 Using the 1000 genome phase 3 dataset, we failed to detect any LD among the 3 variants in both European and East Asian populations (data not shown here). On screening the SNCA locus in the COURAGE-PD dataset, we observed nominal significance of all the 3 variants (PCOURAGE (rs356203) = 0.035, PCOURAGE (rs3775458) = 0.005, and PCOURAGE (rs983361) = 0.022), possibly suggesting a consistence influence of different loci around the SNCA region in determining AAO in different worldwide PD populations. The combination of our dataset with IPDGC further showed an independent genome-wide significant signal originating from the 3′ end of the SNCA gene (rs983361), as shown in the Results section above. Notably, we also observed an independent signal at the 5′ end (rs356203). However, the variant was excluded for further interpretation because of high heterogeneity observed when combining IPDGC and COURAGE datasets (β(SE)COURAGE+IPDGC = −0.591(0.097), PCOURAGE+IPDGC = 9.28 × 10−10; I2 = 61.9%).
Another PD locus, TMEM175, was previously shown to reach genome-wide significance in an AAO study.37 Similar to SNCA, our study also demonstrated replication of the TMEM175 locus in the COURAGE-PD AAO dataset with a nominal level of significance (p = 0.018). The subsequent combination of the nonsynonymous coding variant, rs3431186 (p.M393T), representing the genome-wide significant locus, in the IPDGC dataset with the COURAGE-PD, resulted in the suggestive level of association without any underlying heterogeneity (PCOURAGE+IPDGC = 2.64 × 10−7; I2 = 0.0). On the contrary, a recent East Asian GWAS failed to observe any signal originating from the locus, possibly suggesting the contribution of the locus mainly in the European populations.9 A previous study also reported a borderline significant association of the variant rs429358, representing the APOE ε4 locus with PD-AAO (p = 5.69 × 10−8) in a combined dataset (n = 28,568) comprising IPDGC and 23andMe datasets.7 The study, however, suggested that the association at the locus could be an age-related effect, with a highly significant association with the age of controls (p = 1.49 × 10−5). The variant also resulted in a suggestive association on merging of the COURAGE-PD European dataset only with the IPDGC dataset (p = 9.3 × 10−7). These findings are consistent with the failure to detect the association of APOE ε4 locus with PD-AAO in the recently reported East Asian GWAS.9 However, being a longevity marker, the suggestive finding of the APOE ε4 locus in Europeans must be interpreted with caution.
Our study has several strengths and limitations. Our study provides the largest independent dataset for testing the reliability of previously discovered AAO loci in a highly diverse and predominantly European population. Another strength of our study was the availability of data on AAO on all the study participants as opposed to the age at diagnosis, often used as a proxy for AAO. One of the significant limitations of our findings was the lack of ready access to the recently published East Asian AAO GWAS dataset that prevented us from drawing any conclusion on the validity of the novel BST1 locus in the East Asian population. Likewise, the unavailability of the 23andMe dataset to us has precluded us from making an unequivocal claim on our BST1 findings. Hopefully, the inclusion of other datasets, such as 23andMe and East Asian GWAS datasets, will help further to refine the signals originating from the BST1 locus. We also suggest that loci identified through meta-analysis in the COURAGE-PD dataset (PDZPH1P) and subsequent stratification by gender (RHEB, MTHFD1L, and KNH3) and ethnicity (MOAP1/TMEM251 and SUGCT) be meta-analyzed with these unavailable datasets. Another limitation was our inability to conduct gene-gene interaction because of the limited sample size in this study. The possibility of complex interactions among various loci on Chr 4 in modulating AAO cannot be ruled out. A recent study showed the association of several genome-wide significant loci on the X Chr with PD.38 It is also possible that some of these variants may also modulate AAO. However, owing to potential analytic challenges from calling and imputation of X Chr genotypes, to model uncertainty associated with random X Chr inactivation, we excluded the X Chr variants from the present analysis.39 And finally, it is hoped that in the future, the availability of a larger dataset would enable us to integrate additional layers of genetic data, including rare and copy number variants.40
Our findings clearly highlight the importance of combining GWAS from diverse populations, representative of worldwide populations, to refine the genetic architecture underlying a complex trait such as AAO. Our COURAGE-PD dataset suggests a role for additional pathways in addition to α-synuclein mechanisms of modulating PD pathogenesis and influencing AAO in worldwide PD populations.

Glossary

AAO
age at onset
Chr
chromosome
COURAGE-PD
Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease
eQTL
expression quantitative trait locus
GTEx
Genotype-Tissue Expression
GWAS
genome-wide association studies
IPDGC
International Parkinson Disease Genomics Consortium
LD
linkage disequilibrium (LD)
PD
Parkinson disease
PRS
polygenic risk score
QQ
quantile-quantile
SNV
single-nucleotide variation
UKBEC
UK Brain Expression Consortium

Appendix Authors

Footnote

References

1.
Soldner F, Stelzer Y, Shivalila CS, et al. Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression. Nature. 2016;533(7601):95-99.
2.
Lill CM. Genetics of Parkinson's disease. Mol Cell Probes. 2016;30(6):386-396.
3.
Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284-2303.
4.
Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014;46(9):989-993.
5.
Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet. 2017;49(10):1511-1516.
6.
Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-1102.
7.
Blauwendraat C, Heilbron K, Vallerga CL, et al. Parkinson's disease age at onset genome-wide association study: defining heritability, genetic loci, and α-synuclein mechanisms. Mov Disord. 2019;34(6):866-875.
8.
Jinn S, Drolet RE, Cramer PE, et al. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation. Proc Natl Acad Sci U S A. 2017;114(9):2389-2394.
9.
Li C, Ou R, Chen Y, et al. Genetic modifiers of age at onset for Parkinson's disease in Asians: a genome-wide association study. Mov Disord. 2021;36(9):2077-2084.
10.
Foo JN, Chew EGY, Chung SJ, et al. Identification of risk loci for Parkinson disease in Asians and comparison of risk between Asians and Europeans: a genome-wide association study. JAMA Neurol. 2020;77(6):746-754.
11.
Grover S, Kumar-Sreelatha AA, Bobbili DR, et al. Replication of a novel Parkinson's locus in a European ancestry population. Mov Disord. 2021;36(7):1689-1695.
12.
Zhan X, Hu Y, Li B, Abecasis GR, Liu DJ. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. Bioinformatics. 2016;32(9):1423-1426.
13.
Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genome wide association scans. Bioinformatics. 2010;26(17):2190-2191.
14.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-748.
15.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
16.
Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26(18):2336-2337.
17.
Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47:291-295.
18.
Choi SW, Mak TS, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759-2772.
19.
Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med. 2002;21(1):35-50.
20.
Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648-660.
21.
Ramasamy A, Trabzuni D, Guelfi S, et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat Neurosci. 2014;17(10):1418-1428.
22.
Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41(12):1303-1307.
23.
Li J, Luo J, Liu L, Fu H, Tang L. The association between CD157/BST1 polymorphisms and the susceptibility of Parkinson's disease: a meta-analysis. Neuropsychiatr Dis Treat. 2019;15:1089-1102.
24.
Sharma M, Ioannidis JP, Aasly JO, et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012;79(7):659-667.
25.
Kaisho T, Ishikawa J, Oritani K, et al. BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth. Proc Natl Acad Sci U S A. 1994;91(12):5325-5329.
26.
Fliegert R, Gasser A, Guse AH. Regulation of calcium signalling by adenine-based second messengers. Biochem Soc Trans. 2007;35(pt 1):109-114.
27.
Ortolan E, Augeri S, Fissolo G, Musso I, Funaro A. CD157: from immunoregulatory protein to potential therapeutic target. Immunol Lett. 2019;205:59-64.
28.
Kasai S, Yoshihara T, Lopatina O, Ishihara K, Higashida H. Selegiline Ameliorates depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson's disease. Front Behav Neurosci. 2017;11:75.
29.
Lopatina O, Yoshihara T, Nishimura T, et al. Anxiety- and depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson's disease. Front Behav Neurosci. 2014;8:133.
30.
Quarona V, Zaccarello G, Chillemi A, et al. CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom. 2013;84:207-217.
31.
Higashida H, Liang M, Yoshihara T, et al. An immunohistochemical, enzymatic, and behavioral study of CD157/BST-1 as a neuroregulator. BMC Neurosci. 2017;18(1):35-35.
32.
Jin D, Liu HX, Hirai H, et al. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature. 2007;446(7131):41-45.
33.
Shen YT, Wang JW, Wang M, et al. BST1 rs4698412 allelic variant increases the risk of gait or balance deficits in patients with Parkinson's disease. CNS Neurosci Ther. 2019;25(4):422-429.
34.
Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276(5321):2045-2047.
35.
Pihlstrøm L, Blauwendraat C, Cappelletti C, et al. A comprehensive analysis of SNCA-related genetic risk in sporadic Parkinson disease. Ann Neurol. 2018;84:117-129.
36.
Du B, Xue Q, Liang C, et al. Association between alpha-synuclein (SNCA) rs11931074 variability and susceptibility to Parkinson's disease: an updated meta-analysis of 41,811 patients. Neurol Sci. 2020;41(2):271-280.
37.
Blauwendraat C, Reed X, Krohn L, et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain. 2020;143(1):234-248.
38.
Le Guen Y, Napolioni V, Belloy ME, et al. Common X-chromosome variants are associated with Parkinson disease risk. Ann Neurol. 2021;90:22-34.
39.
Deng WQ, Mao S, Kalnapenkis A, et al. Analytical strategies to include the X-chromosome in variance heterogeneity analyses: evidence for trait-specific polygenic variance structure. Genet Epidemiol. 2019;43(7):815-830.
40.
Rudakou U, Yu E, Krohn L, et al. Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations. Brain. 2021;144(2):462-472.
Letters to the Editor

Information & Authors

Information

Published In

Neurology®
Volume 99Number 7August 16, 2022
Pages: e698-e710
PubMed: 35970579

Publication History

Received: November 17, 2021
Accepted: March 23, 2022
Published online: May 26, 2022
Published in print: August 16, 2022

Permissions

Request permissions for this article.

Disclosure

M. Sharma is supported by the grants from the German Research Council (DFG/SH 599/6-1), MSA Coalition, and Michael J. Fox Foundation. This work was also supported by grants from the Luxembourg National Research Fund (FNR) within the PEARL programme (FNR/P13/6682797 to R. Krüger) and the National Centre for Excellence in Research on Parkinson's disease (NCER-PD to R. Krüger, P. May, and Z. Landoulsi). Z. Landoulsi and P. May were supported by the DFG Research Unit FOR2715 (INTER/DFG/17/11583046) and FOR2488 (INTER/DFG/19/14429377). C. Domenighetti is the recipient of a doctoral grant from Université Paris-Saclay, France. T. Gasser reports personal fees from UCB Pharma, personal fees from Novartis, personal fees from Teva, personal fees from MedUpdate, grants from the Michael J. Fox Foundation for Parkinson's Research, grants from Bundesministerium für Bildung und Forschung (BMBF), grants from Deutsche Forschungsgemeinschaft (DFG), and other from “Joint Programming for Neurodegenerative Diseases” (JPND) program, funded by the European Commission, outside the submitted work; in addition, T. Gasser has a Patent Number: EP1802749 (A2) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders issued. D. Krainc is the Founder of Lysosomal Therapeutics Inc. and Vanqua Bio; serves on the scientific advisory boards of the Silverstein Foundation, Vanqua Bio, Intellia Therapeutics, and Prevail Therapeutics; and is a Venture Partner at OrbiMed. BvdW received research support from Radboud University Medical Center, ZonMw, Gossweiler Foundation, and Hersenstichting and has served on a scientific advisory board of uniQure. The remaining authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

The COURAGE-PD Consortium is conducted under a partnership agreement between 35 studies. The COURAGE-PD Consortium is supported by the EU Joint Program for Neurodegenerative Disease Research (JPND; neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/closed-calls/risk-factors-2012/risk-factor-call-results/courage-pd/, Grant ID: 01ED1406).

Authors

Affiliations & Disclosures

From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ashwin Ashok Kumar Sreelatha, MTech
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Consultancy for Roche 2021, honoraria paid to my institution.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Southeastern Norway Regional Health Authority, project leader, PhD-grants, 2017-current and 2019-current
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Norwegian Health Association (2) Michael J. Fox Foundation (3) Norwegian Parkinson Disease Research Fund (4) Reberg's Legacy
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
doctoral grant from Universit&#x00E9; Paris-Saclay
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Claudia Schulte, MSC
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Pierre-Emmanuel Sugier, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Association France Parkinson
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Milena Radivojkov-Blagojevic, MSc
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Peter Lichtner, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Océane Mohamed, MSc
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Berta Portugal, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Zied Landoulsi, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
FOR2715: INTER/DFG/17/11583046 BMBF Treat-ION grant: 01GM1907 NCER-PD: FNR112641 FNR Core MiRisk-PD: C17/BM/11676395
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Dheeraj Bobbili, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) DFG Research Unit FOR2715 (INTER/DFG/17/11583046)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Maximilian Hanussek, MSc https://orcid.org/0000-0002-2598-4398
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Fujitsu TDS, Senior IT Solution Architect, 0,16 years (2 months)
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Journal of Integrative Bioinformatics, Editorial board
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Dena G. Hernandez, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Government employee NIH Biologist
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Cornelis Blauwendraat, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
George D. Mellick, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Australian National Health and Medical Research Council, APP1010225, PI, 2011-2013. Parkinson's Queensland Inc Geriatric Medical Foundation Clem Jones Foundation
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Geriatric Medical Foundation of Queensland, (2)Parkinson's Queensland Incorporated
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Alexander Zimprich, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Walter Pirker, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
Stada, AbbVie Pharma, Bial and Boehringer Ingelheim Funding for travel or speaker honoraria: Travel grants and eductional support: Boehringer Ingelheim and AOP Pharma Lecturing honoraria: Boehringer Ingelheim, UCB, Bial, AOP Orphan, AbbVie and Medtronic
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Manuela Tan, MSC
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Parkinson's UK, (2) Michael J Fox Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ekaterina Rogaeva, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
(1) the Canadian Consortium on Neurodegeneration in Aging Research Support, Foundations and Societies: (1) the Canadian Consortium on Neurodegeneration in Aging
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Anthony Lang, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
AbbVie, AFFiRis, Biogen, BioAdvance, BlueRock, BMS, Denali, Janssen, Lilly, Paladin, Retrophin, Roche, Sun Pharma, and UCB
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Sun Pharma, AbbVie, Paladin, and Sunovion
Editorial Boards:
1.
Movement Disorders Clinical Practice Journal of Neurology, Neurosurgery and Psychiatry Annals of Neurology
Patents:
1.
NONE
Publishing Royalties:
1.
Schapira A, Lang AE, Fahn S. Movement Disorders 4. Saunders, Elsevier, Philadelphia, PA 2009. Olanow CW, Stocchi F, Lang AE. The Non-motor and Non-Dopaminergic Features of Parkinson’s Disease. Wiley-Blackwell, UK. 2011. Weiner WJ, Shulman LM, Lang AE. Parkinson’s Disease: A Complete Guide for Patients and Families. The Johns Hopkins University Press, Baltimore. 2001 Receives publishing royalties from Cambridge University Press.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Parkinson's UK MSA Coalition Defeat MSA Van Andel Institute
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Brain Canada, Canadian Institutes of Health Research Ontario Brain Institute
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, Parkinson Foundation, Parkinson Canada, W. Garfield Weston Foundation Rossy Family Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Experimental Biology and Medicine Scientific Reports BMC Medical Genetics
Patents:
1.
A METHOD OF PRODUCING BIOTECHNOLOGICAL DRUGS USING TRANSGENIC BOVINE ANIMALS
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Pille Taba, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Suzanne Lesage, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Biomed Research International 2014-2015 Frontiers in Neurology 2019-2021 Genes - MDPI 2021-2022
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
The Fondation pour la Recherche M&#x00E9;dicale (MND202004011718) 2021-2024
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Alexis Brice
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
(1) FWO (Research Foundation Flanders), (2) ERC (European Research Council), (3) BMBF (Bundesministeriums f&#x00FC;r Bildung and Forschung-Berlin Germany), (4) UNILUX LCSB (Luxembourg University), (5) UKDRI (UK Dementia Research Institute HQ)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1)Neurology and Clinical Neuroscience, Editorial Board Member, 2012-,(2)Parkinsonism and Related Disorders,Editorial Board Member,2008-,(3)Brain,Editorial Board Member,2007-,(4)The Cerebellum, Editorial Board Member, 2001-,(5) Neurogenetics, Editorial Board Member, 2001-
Patents:
1.
(1) Licencing with ATHENA DIAGNOSIS during the 2012-2016 period: Diagnosis of hereditary spastic paraplegias (HSP) by identification of a mutation in the KIAA1840 gene or protein. National submission by INSERM Transfert September 11, 2006. International extension September 11 2007; demand n&#x00B0; PCT/IB2007/003535, publication n&#x00B0; WO/2008/032218 dated March 20 2008 (2) Boukhris A, Brice A, Goizet C, Hanein S, Martin E, Stevanin G. Diagnosis of hereditary spastic paraplegias (HSP) by identification of a mutation in the ZFYVE26 gene or protein. National submission by INSERM Transfert April 2 2008. International extension March 31 2009 n PCT/EP2009/053838, publication n&#x00B0; WO/2009/121897 (A1) dated October 10 2009.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
For my wife: (1)NIH #2007002IN / READISCA-Biogen, Lead Investigator, 2019-2023, (2)NIH #1712002IN/READISCA, Lead Investigator, 2018-2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1)France Parkinson Association (FRC), (2) ENP, (3)ARN-EPIG, (4)CHU de Nimes, (5)Institut de France-Prix Allianz, For my wife : (6)AFAF, (7)AFAF, (8)Acad&#x00E9;mie des Sciences, (9)ANR-ERA NET E RARE / SCA-CYP, (10)ANR - PRCE / Hdcyp, (11)ABM - Agence de la BioM&#x00E9;decine / RISQUINFO,
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
(1) Licencing with ATHENA DIAGNOSIS for 2012-2016 period: Diagnosis of hereditary spastic paraplegias (HSP) by identification of a mutation in the KIAA1840 gene or protein. National submission by INSERM Transfert September 11, 2006. Publication n&#x00B0; WO/2008/032218 dated March 20 2008, (2) Diagnosis of hereditary spastic paraplegias (HSP) by identification of a mutation in the ZFYVE26 gene or protein. National submission by INSERM Transfert April 2 2008. N&#x00B0;PCT/EP2009/053838, publication n&#x00B0; WO/2009/121897 (A1) dated October 10 2009.
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jean-Christophe Corvol, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
Advisory board for Pfizer, Theranexus, Zambon, and BMS
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Speaker honoraria from Zambon, travel grant from Zambon and Abbvie
Editorial Boards:
1.
Movement Disorders journal, associate editor, 2015
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Research grant from Actelion and Sanofi
Research Support, Government Entities:
1.
Grants from the French Ministry of Health, ANR
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Grant from the Michael J Fox Foundation, France Parkinson
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Marie-Christine Chartier-Harlin, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
invited editor for cells
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
executive board of Fondation Vaincre Alzheimer
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
ANR &#x0096;Agence nationale de recherche, 4 grants: (1)ANR-16-CE16-0012-02 MeTDePaDi, 2017-2021; ( (2)ANR- JPND 2017-2022 pathway analysis - TransNeuro,(3)ANR-20-CE16- 0008 Synapark,2020-2024; (4)ANR-21-CE16-0003-01 PARK-PEP, 2021-2024, CoPi and Investigator
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1)Fondation de France (Maladie de Parkinson, R19199EK), 2 grants 2020-2021and 2022-2023 CoPI (2)Michael J. Fox Foundation, 3 grant numbers 6709.03, 10255.03, and 12938.04, CoPI
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Eugenie Mutez, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) speaker honoraria from Merz Research Support, Academic Entities: CHU Lille Signature: /Eugenie Mutez/ Date: 08 FEB 2022
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Kathrin Brockmann, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
KB has received honoraria for lectures from GlaxoSmithKline, Lundbeck, Orion Pharma, UCB, and Zambon as well as travel grants from the Movement Disorders Society.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
BMBF
Research Support, Academic Entities:
1.
1. the University of Tuebingen (Clinician Scientist) 2. the German Centre for Neurodegenerative Diseases (DZNE, MIGAP). Research Support, Foundations and Societies: 1. the German Society of Parkinson&#x0092;s disease (dpv); 2. the Michael J. Fox Foundation (MJFF)
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Angela B. Deutschländer, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
AD is supported by a gift from Carl Edward Bolch, Jr, and Susan Bass Bolch AD is supported by the Sol Goldman Charitable Trust.
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Manus Neurodynamica
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Allergan Medical Education grant
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Georges M. Hadjigeorgiou, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Efthimos Dardiotis, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Leonidas Stefanis, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
1) Abbvie 2) ITF Hellas 3) Biogen
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
1) Associate Editor, Experimental Neurology 2) Associate Editor, Parkinsonism and Related Disorders, 2022-
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
GSRT grant on
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
MJFF: PPMI, Head of Athens site, 2013-2021 MJFF: PPMI2, Head of Athens site, 2021-
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Athina Maria Simitsi, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
I recieved funding from the Michael J. Fox Foundation for my participation to the PPMI Study (Parkinson's Progression Markers Initiative).
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Enza Maria Valente, MD, PhD https://orcid.org/0000-0002-0600-6820
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Journal of Medical Genetics, Associate Editor, 2016-2022 (2) Pediatric Research, Genetic Section Editor, 2010-2022 (3) Movement Disorders Clinical Practice, Member of the Editorial Board, 2019-2022
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Ministry of Health (Bando Ricerca Finalizzata 2019), grant nr. RF-2019-12369368, PI, 2021-2024 (2) Telethon Foundation Italy, grant nr. GGP20070, PI, 2021- 2024 (3) EraNet Neuron, grant nr. NEURON_NDD-120 (NDCil), PI, 2022- 2025
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Simona Petrucci, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Anna Zecchinelli, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
1) BIAL pharmaceuticals
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
1)Sponsorship for MDS congress from Zambon pharmaceuticals 2)Sponsorship for ACCADEMIA LIMPE-DISMOV from Zambon pharmaceuticals
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
1)speaker for ABBVIE pharmaceuticals 2) Speaker for Zambon pharmaceuticals
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Laura Brighina, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Carlo Ferrarese, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
Scientific Advisory Board of Gantenerumab Study (Roche) Scientific Advisory Board of Merck Scientific Advisory Board od DOC Scientific Advisory Board of Biogen
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Travel reimbursement from Roche to attend Advisory Board of Gatenerumab in San Diego (Nov. 2013) Travel reimbursement from Merck to attend Advisory Board (Rome, March 2018)
Editorial Boards:
1.
Member of editorial board of Neurological Sciences since 2011. No compensation Associate Editor of Parkinson Disease (no compensation)
Patents:
1.
NONE
Publishing Royalties:
1.
Textbook: Malattie del sistema nervoso, McGraw Hill, 2016
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
1. Roche 2. Merck 3. Biogen 4. DOC
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Grazia Annesi, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Andrea Quattrone, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
LIMPE-DISMOV Academy. SEGALA grant for young researchers.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Monica Gagliardi, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Lena F. Burbulla, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. [948027]) (2) German Research Foundation (DFG) under Germany's Excellence Strategy within the framework of the Munich Cluster of Systems Neurology (EXC 2145 SyNergy &#x0096; ID 390857198).
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Hirotaka Matsuo, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Yusuke Kawamura, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Nobutaka Hattori, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Movement Disorders-Clinical Practice, Journal of Neural Transmission, Neuroscience Research, JNNP, J of Parkinson's disease
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Hisamitsu Pharmaceutical, Dai-Nippon Sumitomo Pharma Co.,Ltd., Kyowa Hakko Kirin,
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Kenya Nishioka, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sun Ju Chung, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Journal of Clinical Neurology, Editorial Board, 7 years (2) Journal of Movement Disorders, Editor-in-Chief, 4 years
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Lukas Pavelka, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Bart P.C. van de Warrenburg, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
Scientific advisory board of uniQure (commercial)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
UKM Medical centre, Kuala Lumpur, Malaysia (non-profit)
Editorial Boards:
1.
1. Review Editor for Frontiers in Neurology (section Movement Disorders), 2011 - present 2. Member editorial board of Cerebellum & Ataxias, 2014 - 2021 All without compensation.
Patents:
1.
NONE
Publishing Royalties:
1.
Leerboek Neurologie, Bohn-Stafleu-van Loghum (2018) - contributed to one chapter (royalties to department)
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
ZonMW, 9003037604 and 733051066, funding agency, 2016 - present
Research Support, Academic Entities:
1.
(1) Radboud University Medical Center, Nijmegen, the Netherlands Research Support, Foundations and Societies: Hersenstichting Gossweiler Foundation
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Bastiaan R. Bloem, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
(1) Abbvie (commercial entity); (2) Biogen(commercial entity); (3) UCB (commercial entity); (4) Neuroderm (commercial entity) (5) Michael J. Fox Foundation (non profit entity)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) AbbVie (speaker's fee) (commercial entity); (2) Zambon (speaker's fee) (commercial entity); (3) Bial (speaker's fee) (commercial entity); (4) Roche (speaker's fee) (commercial entity) (5) GE Healthcare(speaker's fee) (commercial entity) (6) UCB (speaker's fee) (commercial entity) (7) Oruen (speaker's fee) (commercial entity)
Editorial Boards:
1.
(1) Journal of Parkinson's Disease, co-Editor in Chief (2010-present) (no compensation); (2)Practical Neurology, member editorial board (2018 - present)(no compensations) (3)Digital Biomarkers, member editorial board (2017- present (no compensations) (4) The Movement Disorder Society (currently Secretary) (5) Michael J Fox Foundation for Parkinson Research, member of the Executive Scientific Advisory Board
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Zambon (commercial entity) UCB (commercial entity) Abbvie (commercial entity) Kyowa Kirin (commercial entity) Critical Path Institute (non profit entity)
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) UCB (commercial entity); (2) AbbVie (commercial entity); (3) Verily (commercial entity).
Research Support, Government Entities:
1.
(1) A smartphone based, titrated exercise solution for patients with Parkinson's disease in daily life. Grant of ZonMw. Role: project leader. 2019 (2) Proactive and Integrated Management and Empowerment in Parkinson&#x0092;s Disease (PRIME-PD). Grant of the Gatsby Foundation. Role: project leader. 2018 (3) Vibrating socks: a novel cueing intervention to reduce freezing of gait in Parkinson&#x0092;s disease. Grant of the Michael J Fox Foundation. Role: project leader. 2018 (4) The PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation. Grant of the Michael J Fox Foundation. Role: project leader.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Netherlands Organization for Scientific Research (non- profit entity); (2) Michael J Fox Foundation (non-profit entity); (3) Parkinson Vereniging (non-profit entity); (4) Stichting Parkinson Fonds (non-profit entity); (5) National Parkinson Foundation (non-profit entity); (6) Hersenstichting (non-profit entity) (7) Gatsby foundation (non-profit entity)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Andrew B. Singleton, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Serve on: Lancet Neurology Neurogenetics Neurobiology of Disease Neurodegenerative Diseases Brain Journal of Parkinson's Disease Movement Disorders
Patents:
1.
Royalties received for panel of markers to diagnose stroke
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Royalties received for panel of markers to diagnose stroke
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Michael J Fox Foundation for Parkinson's Research Aligning Science Across Parkinson's Initiative
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jan Aasly, MD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Parkinson's disease;
Patents:
1.
Patent for LRRK2 G2019S
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editorial board member of PLOS One, Frontiers in Neurology.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Research Council of Norway, grant number 238920, principal investigator, 2014 (2) Regional Health Authority South-Eastern Norway, Career award, 2016
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Leonor Correia Guedes, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Joaquim J. Ferreira, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
(1) BIAL (2) Lundbeck (3) Biogen (4) Abbvie (5) Sunovion Pharmaceuticals (6) Affiris
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Journal of Parkinson Disease
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
(1) Faculty of Medicine, University of Lisbon; (2) CNS - Campus Neurol&#x00F3;gico S&#x00E9;nior
Consultancies:
1.
(1) GlaxoSmithKline, (2) Novartis, (3) TEVA, (4) Lundbeck, (5) Solvay, (6) BIAL, (7) Merck-Serono, (8) Merz, (9) Ipsen, (10) Biogen, (11) Acadia, (12) Allergan, (13) Abbvie, (14) Sunovion Pharmaceuticals, (15) Biogen, (17) Affiris
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) GlaxoSmithKline, (2) Grunenthal, (3) Funda&#x00E7;&#x00E3;o MSD (Portugal), (4) TEVA, (5) MSD, (6) Allergan, (7) Novartis, (8) Medtronic.
Research Support, Government Entities:
1.
(1)Funda&#x00E7;&#x00E3;o para Ci&#x00EA;ncia e Tecnologia (Portugal); Care for Late Stage Parkinsonism (JPND-HC/0002/2012); Principal Investigator; 2014-2017. (2) Funda&#x00E7;&#x00E3;o para Ci&#x00EA;ncia e Tecnologia (Portugal); COmprehensive Unbiased Risk factor Assessment for Genetics and Environment in Parkinson&#x0091;s Disease (JPND-RF/0001/2012); Principal Investigator; 2014- 2017. (3) Funda&#x00E7;&#x00E3;o para Ci&#x00EA;ncia e Tecnologia (Portugal); Dysarthria in Parkinson&#x0092;s disease: Lusophony vs. Francophony comparison (FCT-ANR/NEU-SCC/0005/2013); Principal Investigator; 2014-2018. (4) H2020; Conservative iron chelation as a disease-modifying strategy in Parkinson&#x0092;s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone (FAIR-PARK II); Principal Investigator; 2015-2020.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
(1) Novartis, (2) Bial
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Scientific Reports - On Editorial Board, 2015
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
South African Medical Research Council [Self-Initiated Research Grant]; The National Research Foundation of South Africa [grant Numbers:129249]
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jonathan Carr, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Eduardo Tolosa, MD, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
honoraria as a speaker for UCB, Boeringer Ingelheim, Novartis, Abbot, Medtronic, Solvay, GSK, Teva
Editorial Boards:
1.
Editorial advisory board member for Journal Neurological Sciencies
Patents:
1.
Date of filing: 17.12.2015 Title: method for the sub-classification of patients suffering from parkinson disease
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
TEVA, Bial, Prevail Therapeutics, Boehringer Ingelheim, Roche and BIOGEN
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Mario Ezquerra, PhD
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team “Exposome, heredity, cancer and health,” CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172—JPArc—Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences—Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Te